Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
Back

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Recruiting

Open to: ALL

Age: 12.0 - 80.0

London Southampton Liverpool Belfast

Medical Conditions

Asthma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..

Study details include:

1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2024 Jun 2027

INTERVENTIONAL

Intervention Type : COMBINATION_PRODUCT
Intervention Description : IMP. Subcutaneous injection. Unit dose strengths 210 mg.

Intervention Arm Group : Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS;Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS;Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS;

Intervention Type : COMBINATION_PRODUCT
Intervention Description : AxMP. Oral inhalation. High-dose: 160 ÎĽg/4.5 ÎĽg per inhalation; Medium and Low-dose: 80 ÎĽg/4.5 ÎĽg per inhalation

Intervention Arm Group : Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS;Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS;Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS;

Intervention Type : COMBINATION_PRODUCT
Intervention Description : AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 ÎĽg/80 ÎĽg per inhalation In US only.

Intervention Arm Group : Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS;Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS;Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS;

Intervention Type : COMBINATION_PRODUCT
Intervention Description : NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

Intervention Arm Group : Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS;Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS;Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS;

Intervention Type : COMBINATION_PRODUCT
Intervention Description : AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 ÎĽg per inhalation

Intervention Arm Group : Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS;Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    London
    SE1 9RT
  • Research Site
    Southampton
    SO16 6YD
  • Research Site
    Liverpool
    L7 8XP
  • Research Site
    Belfast
    BT9 7BL

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com



The study is sponsored by AstraZeneca and is in collaboration with Fortrea.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06473779
Last updated 20 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top